Altreno is a topical treatment for acne vulgaris, primarily for patients who are 9 years or older. It's active ingredient is tretinoin. The drug, owned by Dow Pharm, was first authorized for market use on August 23, 2018, and is available in lotion or topical dosage forms.
The generic version of Altreno will likely be available after August 22, 2038. This is based on the expiry date of its last patent (US11324710). There are no signs of any Para IV filings, suggesting that generic competition will only emerge once the patent expires.
Altreno's active ingredient, tretinoin, plays a crucial role in its effectiveness. tretinoin is a form of vitamin A that helps the skin renew itself, making it an effective solution for acne treatment.
Altreno has a total of 2 patents, both titled 'Topical pharmaceutical compositions for treating skin conditions,' and both set to expire on August 22, 2038. There doesn't seem to be any Para IV filings, which means that Altreno's generic version will only be available after the last patent expires. Below are the details of the patent: